PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
ORGANIZATION
PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
The Pharmaceutical Research and Manufacturers of America (PhRMA) raised alarm over Tokyo’s response to the US most-favored-nation (MFN) pricing policy on April 17, warning that failure to act could make drug launches in Japan less commercially viable. Speaking at a…
To read the full story
Related Article
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
- Pfizer Japan President Igarashi Takes Helm as PhRMA Japan Chair
January 6, 2026
- PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
November 19, 2025
- No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
ORGANIZATION
- UA Zensen Targets 6% Wage Hike Demand for 2027
October 28, 2026
- JaDHA Keen to Grab Chuikyo Seat to Speed Reimbursement for Digital Health
October 27, 2026
- FPMAJ Urges Member Groups to Share Government PHP Security Alert
October 26, 2026
- JPWA Reports No Damage from PHP Vulnerability, Renews “No” to FY2027 Revision
October 23, 2026
- Ex-JMA Vice President, Lawmaker Hanyuda Remembered at Memorial Service
October 21, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…